Why Akorn (AKRX) Is Down Today

NEW YORK (TheStreet) -- Akorn  (AKRX) was falling 8.75% to $23.56 on Monday after the generic pharmaceutical company issued first-quarter guidance that came up short of analysts' expectations.

The company said it expects earnings per share of 76 cents to 79 cents in the first quarter, below the Capital IQ consensus estimate of 86 cents a share. The company said it expects full-year revenue of $540 million to $560 million, which surpasses the consensus estimate of $500.99 million.

For the fourth quarter of 2013, Akorn reported earnings per share of 14 cents, which was exactly in line with the consensus estimate. Revenue rose 18.9% year over year to $85 million, which beat analysts' estimates of $83.4 million.

Must Read: Akorn Reports 2013 Fourth Quarter And Year-End Financial Results

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

AKRX Chart

AKRX data by YCharts

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

More from Markets

Apple and GE Switch Roles; Musk's Super Control of Tesla Explained -- ICYMI

Apple and GE Switch Roles; Musk's Super Control of Tesla Explained -- ICYMI

Trump May Be More to Blame For Higher Oil Prices Than OPEC

Trump May Be More to Blame For Higher Oil Prices Than OPEC

Dow Falls Over 200 Points as Apple's Slump Offsets Gains in General Electric

Dow Falls Over 200 Points as Apple's Slump Offsets Gains in General Electric

Week Ahead: Major Earnings on Tap as Wall Street Readies for Geopolitical Moves

Week Ahead: Major Earnings on Tap as Wall Street Readies for Geopolitical Moves

3 Hot Reads From TheStreet's Top Premium Columnists

3 Hot Reads From TheStreet's Top Premium Columnists